ERBB2 and breast cancer: However, the largest retrospective analysis to date evaluating an association between FCGR3A/2A genotypes and clinical outcome in trastuzumab-treated HER2-positive BC in the adjuvant setting showed no statistically significant correlation between FCGR3A and FCGR2A genotypes and disease-free survival in a cohort of 1286 patients treated with trastuzumab-based therapy in early BC nor in progression-free survival in 53 women treated with trastuzumab-based therapy for metastatic BC (Hurvitz et al., 2012).